Preferred Name |
fluoxymesterone |
|
Synonyms |
Stenox |
|
Definitions |
A halogenated derivative of 17-alpha-methyltestosterone. Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus. This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C507" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C507" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000494707 |
|
altLabel |
Stenox Halotestin FXM Halodrin Oratestin 11Beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one Testoral Androfluorene Ora-Testryl 9Alpha-fluoro-11beta-hydroxy-17alpha-methyltestosterone Androsterolo (11Beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one Android-F Ultandren |
|
CAS Registry |
76-43-7 |
|
Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000040656 http://purl.bioontology.org/ontology/PDQ/CDR0000039468 http://purl.bioontology.org/ontology/PDQ/CDR0000041319 http://purl.bioontology.org/ontology/PDQ/CDR0000041001 http://purl.bioontology.org/ontology/PDQ/CDR0000042160 http://purl.bioontology.org/ontology/PDQ/CDR0000039469 http://purl.bioontology.org/ontology/PDQ/CDR0000041000 http://purl.bioontology.org/ontology/PDQ/CDR0000039531 http://purl.bioontology.org/ontology/PDQ/CDR0000039409 http://purl.bioontology.org/ontology/PDQ/CDR0000039535 http://purl.bioontology.org/ontology/PDQ/CDR0000040979 http://purl.bioontology.org/ontology/PDQ/CDR0000039530 http://purl.bioontology.org/ontology/PDQ/CDR0000039527 http://purl.bioontology.org/ontology/PDQ/CDR0000039392 |
|
cui |
C0016366 C0733927 C0720810 C1517242 C0733925 C0733926 C1517244 C1517243 C1517241 |
|
DATE FIRST PUBLISHED |
2006-07-07 |
|
definition |
A halogenated derivative of 17-alpha-methyltestosterone. Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus. This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C507" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C507" NCI Thesaurus) |
|
IND Code |
4573 |
|
LT |
TRD |
|
NCI ID |
C507 |
|
notation |
CDR0000494707 |
|
NSC Code |
12165 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
fluoxymesterone |
|
tui |
T125 T109 T121 |